HBM Holdings (02142) Enters Exclusive Agreement with Solstice Oncology for HBM4003

Bulletin Express02-23

HBM Holdings (02142) and Solstice Oncology have entered an exclusive license and equity partnership involving HBM4003 outside Greater China. Under the agreement, total upfront consideration exceeds US$105.00 million, comprising a US$50.00 million cash payment, an additional US$5.00 million near-term payment, and over US$50.00 million in equity interest in Solstice Oncology.

Future development, regulatory, and commercial milestones could total up to approximately US$1.10 billion, alongside tiered royalties on net sales outside Greater China. None of the relevant Listing Rules percentage ratios reach 5.00% or more, so no reporting or approval obligations arise in this matter.

The arrangement aims to advance HBM4003 on a global scale. However, there is no assurance that associated products will ultimately succeed in commercial development, and investors are advised to exercise caution when dealing in shares of HBM Holdings.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1187325623?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-23 08:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187325623","market":"us","top_or_hot":-1,"title":"HBM Holdings (02142) Enters Exclusive Agreement with Solstice Oncology for HBM4003","media":"Bulletin Express","content":"<p>HBM Holdings (02142) and Solstice Oncology have entered an exclusive license and equity partnership involving HBM4003 outside Greater China. Under the agreement, total upfront consideration exceeds US$105.00 million, comprising a US$50.00 million cash payment, an additional US$5.00 million near-term payment, and over US$50.00 million in equity interest in Solstice Oncology.</p>\n<p>Future development, regulatory, and commercial milestones could total up to approximately US$1.10 billion, alongside tiered royalties on net sales outside Greater China. None of the relevant Listing Rules percentage ratios reach 5.00% or more, so no reporting or approval obligations arise in this matter.</p>\n<p>The arrangement aims to advance HBM4003 on a global scale. However, there is no assurance that associated products will ultimately succeed in commercial development, and investors are advised to exercise caution when dealing in shares of HBM Holdings.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings (02142) Enters Exclusive Agreement with Solstice Oncology for HBM4003</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings (02142) Enters Exclusive Agreement with Solstice Oncology for HBM4003\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-23 08:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HBM Holdings (02142) and Solstice Oncology have entered an exclusive license and equity partnership involving HBM4003 outside Greater China. Under the agreement, total upfront consideration exceeds US$105.00 million, comprising a US$50.00 million cash payment, an additional US$5.00 million near-term payment, and over US$50.00 million in equity interest in Solstice Oncology.</p>\n<p>Future development, regulatory, and commercial milestones could total up to approximately US$1.10 billion, alongside tiered royalties on net sales outside Greater China. None of the relevant Listing Rules percentage ratios reach 5.00% or more, so no reporting or approval obligations arise in this matter.</p>\n<p>The arrangement aims to advance HBM4003 on a global scale. However, there is no assurance that associated products will ultimately succeed in commercial development, and investors are advised to exercise caution when dealing in shares of HBM Holdings.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02142","symbol_name":"和铂医药-B","start_time":0,"source_url":"","article_id":"1187325623","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187325623","pubTimestamp":1771806229,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"HBM Holdings (02142) and Solstice Oncology have entered an exclusive license and equity partnership involving HBM4003 outside Greater China. Under the agreement, total upfront consideration exceeds...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02142":"和铂医药-B"},"translate_title":"HBM Holdings(02142)与Solstice Oncology就HBM4003达成独家协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1},"content_text":"HBM Holdings (02142) and Solstice Oncology have entered an exclusive license and equity partnership involving HBM4003 outside Greater China. Under the agreement, total upfront consideration exceeds US$105.00 million, comprising a US$50.00 million cash payment, an additional US$5.00 million near-term payment, and over US$50.00 million in equity interest in Solstice Oncology.\nFuture development, regulatory, and commercial milestones could total up to approximately US$1.10 billion, alongside tiered royalties on net sales outside Greater China. None of the relevant Listing Rules percentage ratios reach 5.00% or more, so no reporting or approval obligations arise in this matter.\nThe arrangement aims to advance HBM4003 on a global scale. However, there is no assurance that associated products will ultimately succeed in commercial development, and investors are advised to exercise caution when dealing in shares of HBM Holdings.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187325623","isCrawlerRequest":true}